keyword
https://read.qxmd.com/read/38403942/effects-of-functional-polymorphisms-of-opioid-receptor-mu-1-and-catechol-o-methyltransferase-on-the-neural-processing-of-pain
#21
JOURNAL ARTICLE
Yongjeon Cheong, Seonkyoung Lee, Hidehiko Okazawa, Hirotaka Kosaka, Minyoung Jung
AIM: Pain is reconstructed by brain activities and its subjectivity comes from an interplay of multiple factors. The current study aims to understand the contribution of genetic factors to the neural processing of pain. Focusing on the single-nucleotide polymorphism (SNP) of opioid receptor mu 1 (OPRM1) A118 G (rs1799971) and catechol-O-methyltransferase (COMT) val158 met (rs4680), we investigated how the two pain genes affect pain processing. METHOD: We integrated a genetic approach with functional neuroimaging...
February 25, 2024: Psychiatry and Clinical Neurosciences
https://read.qxmd.com/read/38399483/optimal-post-operative-nalbuphine-dose-regimen-a-randomized-controlled-trial-in-patients-with-laparoscopic-cholecystectomy
#22
JOURNAL ARTICLE
Guan-Yu Chen, Kung-Kai Kuo, Shih-Chang Chuang, Kuang-Yi Tseng, Shen-Nien Wang, Wen-Tsan Chang, Kuang-I Cheng
Background and Objectives : Optimal opioid analgesia is an excellent analgesia that does not present unexpected adverse effects. Nalbuphine, acting on the opioid receptor as a partial mu antagonist and kappa agonist, is considered a suitable option for patients undergoing laparoscopic surgery. Therefore, we aim to investigate the appropriate dosage of nalbuphine for post-operative pain management in patients with laparoscopic cholecystectomy. Materials and Methods : Patients were randomly categorized into low, medium, and high nalbuphine groups...
January 23, 2024: Medicina
https://read.qxmd.com/read/38353935/evaluation-of-the-relationship-of-xylazine-and-fentanyl-blood-concentrations-among-fentanyl-associated-fatalities
#23
JOURNAL ARTICLE
Hannah L Hays, Henry A Spiller, Rebecca T DeRienz, Natalie I Rine, Han-Tian Guo, Meagan Seidenfeld, Nichole L Michaels, Gary A Smith
INTRODUCTION: Illicit fentanyl and fentanyl-analogs have produced a devastating increase in opioid fatalities in the United States. Increasingly, xylazine has been found in the illicit fentanyl supply. The role of xylazine in fentanyl intoxication remains unclear. We reviewed coroner records to evaluate trends and effects associated with xylazine in fentanyl-related fatalities. METHODS: This is a retrospective cohort study of all deaths reported to the Franklin County Coroner's Office in Ohio from 1 January 2019 to 16 March 2023, in which fentanyl was determined causative or contributory to death...
February 14, 2024: Clinical Toxicology
https://read.qxmd.com/read/38338317/novel-1-1-arylimiazolin-2-yl-3-arylalkilurea-derivatives-with-modulatory-activity-on-opioid-mop-receptors
#24
JOURNAL ARTICLE
Dominik Straszak, Sylwia Woźniak, Agata Siwek, Monika Głuch-Lutwin, Marcin Kołaczkowski, Aldona Pietrzak, Bartłomiej Drop, Dariusz Matosiuk
μ-opioid receptor ligands such as morphine and fentanyl are the most known and potent painkillers. However, the severe side effects seen with their use significantly limit their widespread use. The continuous broadening of knowledge about the properties of the interactions of the MOP receptor (human mu opioid receptor, OP3) with ligands and specific intracellular signaling pathways allows for the designation of new directions of research with respect to compounds with analgesic effects in a mechanism different from classical ligands...
January 24, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38328016/opioid-receptor-mu-1-gene-oprm1-a118g-polymorphism-and-emotional-modulation-of-pain
#25
JOURNAL ARTICLE
Edward A Trimble, Parker A Kell, Matteo A Avella, Christopher R France, Jamie L Rhudy
PURPOSE: The A118G polymorphism in the opioid receptor mu 1 gene (OPRM1) is associated with decreased opioid receptor availability, altered emotion, and increased pain. Given that emotions modulate pain (positive emotions inhibit pain, negative emotions enhance pain), we predicted that G allele carriers would experience impaired emotional modulation of pain compared to non-G allele carriers. PATIENTS AND METHODS: Emotional pictures (ie, erotica, neutral, attack) from the International Affective Picture System were used by permission from the authors to experimentally manipulate emotions in 64 adult participants while painful electrocutaneous stimulations were delivered in a cross-sectional study...
2024: Journal of Pain Research
https://read.qxmd.com/read/38320814/are-peripheral-acting-mu-opioid-receptor-antagonists-effective-in-treating-children-with-opioid-induced-constipation
#26
JOURNAL ARTICLE
James Parry-Reece
No abstract text is available yet for this article.
February 6, 2024: Archives of Disease in Childhood
https://read.qxmd.com/read/38320237/opioid-induced-hypogonadism-in-opioid-use-disorder-its-role-in-negative-reinforcement-and-implications-for-treatment-and-retention
#27
JOURNAL ARTICLE
Avery F McGuirt, Christina A Brezing
Hypogonadism is a highly prevalent complication of chronic opioid use associated with a constellation of affective, algesic, and cognitive symptoms as well as decreased quality of life. Given that the mainstays of pharmacologic opioid use disorder (OUD) treatment - methadone and buprenorphine - are themselves agonists or partial agonists at the mu opioid receptor, opioid-induced hypogonadism (OIH) remains an underappreciated clinical concern throughout the course of OUD treatment. Prominent theoretical frameworks for OUD emphasize the importance of negative reinforcement and hyperkatifeia, defined as the heightened salience of negative emotional and motivational states brought on by chronic opioid use...
February 6, 2024: American Journal of Drug and Alcohol Abuse
https://read.qxmd.com/read/38313794/the-impact-of-opioid-receptor-gene-polymorphism-on-fentanyl-and-alfentanil-s-analgesic-effects-in-the-pediatric-perioperative-period
#28
JOURNAL ARTICLE
Jelena Lilic, Vesna G Marjanovic, Ivana Budic, Nikola Stefanovic, Dragana Stokanovic, Goran T Marjanovic, Tatjana Jevtovic-Stoimenov, Mladjan Golubovic, Maja Zecevic, Radmila Velickovic-Radovanovic
INTRODUCTION: The polymorphism of the gene coding mu-opioid receptor ( OPRM1 ) is one of the factors contributing to the variability in the response to opioid analgesics in children. The goal of this study is to investigate its role in association with postoperative acute pain in children of various ages. METHODS: This prospective study analyzed 110 pediatric patients, after plastic or orthopedic surgery, who were genotyped and randomly assigned to receive fentanyl or alfentanil...
2024: Pharmacogenomics and Personalized Medicine
https://read.qxmd.com/read/38305669/review-document-of-the-spanish-association-of-neurogastroenterology-and-motility-on-the-management-of-opioid-induced-constipation
#29
JOURNAL ARTICLE
Jordi Serra, Javier Alcedo, Claudia Barber, Constanza Ciriza de Los Ríos
Opioid induced constipation is a rising problem due to the progressive increment in the prescription of opioids. By contrast to functional constipation, opioid-induced constipation is not a functional gut disorder, but a side effect of the use of opioids. Opioids produce constipation due to a decrease in gastrointestinal motility and a reduction in the gastrointestinal secretions. The treatment of OIC focuses on three basic pillars: optimizing opioid drug indication, preventing constipation onset, and treating it if it occurs...
February 2, 2024: Revista Española de Enfermedades Digestivas
https://read.qxmd.com/read/38301136/efficacy-and-safety-of-low-dose-naltrexone-for-chronic-pain
#30
JOURNAL ARTICLE
Madison N Irwin, David A Cooke, Daniel Berland, Vincent D Marshall, Michael A Smith
Naltrexone is a mu-opioid receptor antagonist increasingly used as an analgesic for chronic pain at low doses. This retrospective, observational cohort study was conducted at an academic medical center to evaluate low-dose naltrexone (LDN) efficacy and describe its use in routine clinical practice. Adults receiving LDN, doses <10 mg for ≥1 month, seen at an outpatient pain clinic from January 1, 2014 to April 1, 2022 were included. The primary outcome was change in the Pain, Enjoyment of Life, and General Activity (PEG) score after LDN...
February 1, 2024: Journal of Pain & Palliative Care Pharmacotherapy
https://read.qxmd.com/read/38277118/dermorphin-d-arg2-lys4-1-4-amide-alleviates-frostbite-induced-pain-by-regulating-trp-channel-mediated-microglial-activation-and-neuroinflammation
#31
JOURNAL ARTICLE
Obulapathi Ummadisetty, Akhilesh, Anagha Gadepalli, Deepak Chouhan, Utkarsh Patil, Surya Pratap Singh, Sanjay Singh, Vinod Tiwari
Cold injury or frostbite is a common medical condition that causes serious clinical complications including sensory abnormalities and chronic pain ultimately affecting overall well-being. Opioids are the first-choice drug for the treatment of frostbite-induced chronic pain; however, their notable side effects, including sedation, motor incoordination, respiratory depression, and drug addiction, present substantial obstacle to their clinical utility. To address this challenge, we have exploited peripheral mu-opioid receptors as potential target for the treatment of frostbite-induced chronic pain...
January 26, 2024: Molecular Neurobiology
https://read.qxmd.com/read/38256863/novel-opioids-in-the-setting-of-acute-postoperative-pain-a-narrative-review
#32
REVIEW
Ashley Wang, Jasper Murphy, Lana Shteynman, Neil Daksla, Abhishek Gupta, Sergio Bergese
Although traditional opioids such as morphine and oxycodone are commonly used in the management of acute postoperative pain, novel opioids may play a role as alternatives that provide potent pain relief while minimizing adverse effects. In this review, we discuss the mechanisms of action, findings from preclinical studies and clinical trials, and potential advantages of several novel opioids. The more established include oliceridine (biased ligand activity to activate analgesia and downregulate opioid-related adverse events), tapentadol (mu-opioid agonist and norepinephrine reuptake inhibitor), and cebranopadol (mu-opioid agonist with nociceptin opioid peptide activity)-all of which have demonstrated success in the clinical setting when compared to traditional opioids...
December 25, 2023: Pharmaceuticals
https://read.qxmd.com/read/38253309/nalbuphine-6-glucuronide-is-a-potent-analgesic-with-superior-safety-profiles-by-altering-binding-affinity-and-selectivity-for-mu-kappa-opioid-receptors
#33
JOURNAL ARTICLE
Yen-Lun Chen, Yen-Hsun Lai, Eagle Yi-Kung Huang, Hong-Jaan Wang, Hao-Yuan Hung
Although nalbuphine, a semi-synthetic analgesic compound, is less potent than morphine in terms of alleviating severe pain, our recent findings have revealed that nalbuphine-6-glucuronide (N6G), one of the glucuronide metabolites of nalbuphine, promotes a significantly more robust analgesic effect than its parent drug. Nevertheless, despite these promising observations, the precise mechanisms underlying the analgesic effects of nalbuphine glucuronides have yet to be determined. In this study, we aim to elucidate the mechanisms associated with the analgesic effects of nalbuphine glucuronides...
January 20, 2024: Life Sciences
https://read.qxmd.com/read/38241153/peripheral-mu-opioid-receptor-activation-by-dermorphin-d-arg2-lys4-1-4-amide-alleviates-behavioral-and-neurobiological-aberrations-in-rat-model-of-chemotherapy-induced-neuropathic-pain
#34
JOURNAL ARTICLE
Anagha Gadepalli, Obulapathi Ummadisetty, Akhilesh, Deepak Chouhan, Krushna Eknath Yadav, Vinod Tiwari
Paclitaxel, a frequently utilized chemotherapeutic agent, often gives rise to severe and distressing sensory neuropathy in patients undergoing chemotherapy. Unfortunately, current therapeutics for chemotherapy-induced neuropathic pain (CINP) demonstrate limited effectiveness and are burdened with the potential for central side effects such as sedation, respiratory depression, cognitive impairment, and addiction, posing substantial clinical challenges. In light of these limitations, present study is designed to investigate the therapeutic potential of Dermorphin [D-Arg2, Lys4] (1-4) amide (DALDA), a preferential peripherally acting mu-opioid receptor agonist, in rat model of CINP...
January 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38232438/stronger-longer-better-opioid-antagonists-nalmefene-is-not-a-naloxone-replacement
#35
JOURNAL ARTICLE
Alexander F Infante, Abigail T Elmes, Renee Petzel Gimbar, Sarah E Messmer, Christine Neeb, Jennie B Jarrett
The fatal overdose crisis claims nearly 200 lives daily in the United States (U.S). Evolutions in the illicit drug supply, such as the addition of sedative adulterants and a shift to synthetic opioids such as fentanyl, have driven increasing rates of both fatal and non-fatal overdose. Specifically, synthetic opioid usage of fentanyl was implicated in 68 % of the U.S. drug overdose deaths in 2022 alone. This has placed tremendous burden on communities, emergency medical services, and healthcare systems, and contributed to tragedy and grief both in the U...
January 16, 2024: International Journal on Drug Policy
https://read.qxmd.com/read/38211933/impact-of-oprm1-mu-opioid-receptor-gene-a112g-polymorphism-on-dual-oxycodone-and-cocaine-self-administration-behavior-in-a-mouse-model
#36
JOURNAL ARTICLE
Yong Zhang, Matthew Randesi, Julie A Blendy, Mary Jeanne Kreek, Eduardo R Butelman
UNLABELLED: The use of mu-opioid receptor (MOP-r) agonists such as oxycodone together with cocaine is prevalent, and deaths attributed to using these combinations have increased. RATIONALE: It is unknown if functional single nucleotide polymorphisms (SNPs), such as the OPRM1 (MOP-r gene) SNP A118G, can predispose individuals to more dual opioid and psychostimulant intake. The dual self-administration (SA) of MOP-r agonists and cocaine has not been thoroughly examined, especially with regard to neurobiological changes...
January 10, 2024: Neuroscience
https://read.qxmd.com/read/38202853/opioid-dopamine-receptor-binding-studies-nmr-and-molecular-dynamics-simulation-of-lenart01-chimera-an-opioid-bombesin-like-peptide
#37
JOURNAL ARTICLE
Pawel Serafin, Łukasz Szeleszczuk, Igor Zhukov, Edina Szűcs, Dávid Gombos, Azzurra Stefanucci, Adriano Mollica, Dariusz Maciej Pisklak, Patrycja Kleczkowska
The design and development of hybrid compounds as a new class of drug candidates remains an excellent opportunity to improve the pharmacological properties of drugs (including enzymatic stability, efficacy and pharmacokinetic and pharmacodynamic profiles). In addition, considering various complex diseases and/or disorders, the conjugate chemistry approach is highly acceptable and justified. Opioids have long been recognized as the most potent analgesics and serve as the basic pharmacophore for potent hybrid compounds that may be useful in pain management...
January 4, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38199273/neurovascular-coupling-alteration-in-drug-na%C3%A3-ve-parkinson-s-disease-the-underlying-molecular-mechanisms-and-levodopa-s-restoration-effects
#38
JOURNAL ARTICLE
Chenqing Wu, Haoting Wu, Cheng Zhou, Xiaojun Guan, Tao Guo, Jingjing Wu, Jingwen Chen, Jiaqi Wen, Jianmei Qin, Sijia Tan, Xiaojie Duanmu, Weijin Yuan, Qianshi Zheng, Baorong Zhang, Xiaojun Xu, Minming Zhang
BACKGROUND: Parkinson's disease (PD) patients exhibit an imbalance between neuronal activity and perfusion, referred to as abnormal neurovascular coupling (NVC). Nevertheless, the underlying molecular mechanism and how levodopa, the standard treatment in PD, regulates NVC is largely unknown. MATERIAL AND METHODS: A total of 52 drug-naïve PD patients and 49 normal controls (NCs) were enrolled. NVC was characterized in vivo by relating cerebral blood flow (CBF) and amplitude of low-frequency fluctuations (ALFF)...
January 8, 2024: Neurobiology of Disease
https://read.qxmd.com/read/38196135/mapping-astrocytic-and-neuronal-%C3%AE-opioid-receptor-expression-in-various-brain-regions-using-mor-mcherry-reporter-mouse
#39
JOURNAL ARTICLE
Woojin Won, Daeun Kim, Eunjin Shin, C Justin Lee
The μ-opioid receptor (MOR) is a class of opioid receptors characterized by a high affinity for β-endorphin and morphine. MOR is a G protein-coupled receptor (GPCR) that plays a role in reward and analgesic effects. While expression of MOR has been well established in neurons and microglia, astrocytic MOR expression has been less clear. Recently, we have reported that MOR is expressed in hippocampal astrocytes, and its activation has a critical role in the establishment of conditioned place preference...
December 31, 2023: Experimental Neurobiology
https://read.qxmd.com/read/38184280/epidural-administration-of-large-dose-of-opioid-%C3%AE-receptor-agonist-may-impair-cardiac-functions-and-myocardial-viability-via-desensitizing-transient-receptor-potential-vanilloid-1
#40
JOURNAL ARTICLE
Xiang Ma, Zheng Guo, Mu-Rong Li, Lu Chen, Xing Zhao, Tian-Qi Wang, Tao Sun
The incidence of postoperative myocardial injury remains high as the underlying pathogenesis is still unknown. The dorsal root ganglion (DRG) neurons express transient receptor potential vanilloid 1 (TRPV1) and its downstream effector, calcitonin gene-related peptide (CGRP) participating in transmitting pain signals and cardiac protection. Opioids remain a mainstay therapeutic option for moderate-to-severe pain relief clinically, as a critical component of multimodal postoperative analgesia via intravenous and epidural delivery...
January 4, 2024: Toxicology and Applied Pharmacology
keyword
keyword
60609
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.